



## WEEKLY EPIDEMIOLOGICAL REPORT

# A publication of the Epidemiology Unit

Ministry of Health

231, de Saram Place, Colombo 01000, Sri Lanka
Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@sltnet.lk
Epidemiologist: +94 11 2681548, E mail: chepid@sltnet.lk
Web: http://www.epid.gov.lk

Vol. 51 No. 43

19th- 25th Oct 2024

The success story of a Melioidosis clinic in a developing country: The Galle experience - Part II

This is the second article of two in a series on "The success story of a Melioidosis clinic in a developing country"

#### Diabetes (DM) and melioidosis

The prevalence of diabetes and chronic kidney disease was 75% (76/102) and 17% (17/102), respectively. Alcoholism and smoking were noted in 30 (29%), each. Among females of > 60 years and 41-60 years, 11 (100%) and 7 (64%) were diabetics, respectively. Among males of >60 yrs and 41-60yrs, 13 (59%) and 38 (93%) were diabetics, respectively (Figure 5). There was a significant association between abscesses/pus formation and the presence of DM (p=0.0388).

Melioidosis antibody titre by the indirect haemagglutination assay was determined in 78 (76%) and there was a significant association of high titres >1:160 with the presence of DM (p=0.044). An ESR >80mm/1<sup>st</sup> hr and high platelet counts (>400000/µL) were significantly associated with DM (p=0.0116 and p=0.0186, respectively). An elevated white cell count (WCC)  $>11000/\mu L$  or mortality was not statistically associated with DM (p=1.000 and p=0.5805 respectively).




Figure 5 - Diabetic and non-diabetic (nDM) by age group and gender

Contents	Page
1. The success story of a Melioidosis clinic in a developing country - Part II	1
2. Summary of selected notifiable diseases reported $(12^{th} - 18^{th} Oct 2024)$	3
3. Surveillance of vaccine preventable diseases & AFP (12th – 18th Oct 2024)	4

#### Clinic follow-up

After the initial in-ward intravenous antibiotic treatment, patients have to undergo a prolonged eradication phase under meticulous monitoring to prevent relapses. This follow-up is a real challenge for several reasons. Most of the patients, being farmers or manual labourers, are from rural areas. Their level of education and understanding of the illness and the importance of compliance with eradication therapy are low. Managing the underlying comorbidities requires a multi-disciplinary approach. Further, many patients were from distant rural areas and found it difficult to attend the clinic.

Despite these constraints, the Melioidosis Clinic of the National Hospital, Galle was established in April 2020, during the COVID-19 pandemic, to cater to these patients, providing individualized care using a multi-disciplinary approach. Held weekly; on Thursdays in the microbiology laboratory premises; it is probably the only clinic in Sri Lanka of that nature dedicated solely to melioidosis patients on eradication phase treatment. Patients are educated, encouraged and motivated to complete the eradication treatment and are followed up until they are discharged from the clinic upon treatment completion. Regular patient follow-ups with proper record keeping are conducted by the four medical officers (microbiology) under the supervision of the Consultant Microbiologist to detect complications of the disease or adverse effects of the eradication treatment. Any febrile illness contracted during or after this period is investigated for a possible relapse. Occasionally, the clinic treats carefully selected patients with acute presentations with only oral drugs on an outpatient basis.

#### What we did

Through the clinic and awareness programmes, we introduced local terminology for the disease i.e. "soil fever" or "panshu una — "当场 分畅" in Sinhalese.

A separate register was opened for melioidosis patients for easier follow-up. All drugs were given through the clinic free of charge as per the government policy. The outpatient pharmacy was collaborating with us very well as they readily issued prescribed drugs even on non-clinic days if needed.

A good rapport was built with each patient and his/her family members to discuss disease-related issues and social and financial constraints.

Laboratory facilities were made available free of charge to monitor disease response and to detect complications of radiation therapy such as bone marrow suppression, renal impairment or hyperkalaemia.

Patients with comorbidities were referred to our collaborators in medical specialities—primarily internal medicine, with occasional referrals to nephrology, endocrinology, and other relevant fields—for consultation and management, which was integral to the success of our work.

Some patients with residual damage were directed to longterm rehabilitation programmes. Many were directed for nutritional advice.

Remote monitoring or advice through voice/WhatsApp video calls was provided when necessary.

Total discharged to follow-up since 2014 – 128 Number successfully followed up – 116 (91%) Adverse effects of drugs and drug adjustment – 18 (14%) Deaths during follow-up (known) – 3 (2%) Relapses – 7 (5.5%) Complications during follow-up – 1 (1%)

#### Take home message

"Melioidosis is a disease where a patient can be saved and his/ her quality of life improved with close follow-up, addressing individual needs and care"

\*These contents were presented as oral and poster presentations at the 10<sup>th</sup> World Melioidosis Congress, held in Darwin, Australia, from 21<sup>st</sup> to 23<sup>rd</sup> October 2024.

#### Compiled by:

Dr.Bhagya Piyasiri, Consultant Microbiologist TH Karapitiya

Dr. Krishantha Jayasekera Consultant Physician TH Karapitiya

Dr. Enoka Corea Professor of Microbiology Faculty of Medicine Colombo

#### References:

 Corea EM, de Silva AD, Thevanesam V. Melioidosis in Sri Lanka. Trop Med Infect Dis. 2018 Feb 21;3(1):22. doi: 10.3390/tropicalmed3010022. PMID: 30274420; PMCID: PMC6136624

Table 1: Selected notifiable diseases reported by Medical Officers of Health 12th - 18th Oct 2024 (42nd Week)

Tab	ie 1	: Selected notifiable diseases reported by Medical Officers of Health 12th-18th Oct 2024 (4										(42	(42 <sup>nd</sup> Week)																
	*.	100	100	100	100	100	100	100	100	100	93	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	66	
WRCD	<u>*</u>	100	100	100	100	100	100	100	100	100	100	100	, 001	100	100	100	100	100	100	100	100	100	100	06	95	100	100	66	
osis	е В	1776 1	997 1	494 1	528 1	104	229 1	374 1	131 1	142 1	222 1	25 1	56 1	34 1	30 1	134 1	104	105 1	415 1	182 1	240 1	91 1	206 1	105	307	308 1	122 1	7395	
Tuberculosis		27 ,	16	_	0	0	9	7	0	0	4	0	0	0	0	~	7	0	2	0	9	0	9	0	0	က	4	2 86	
	A	2	. 53	2	24	9	_	4	<u></u>	4	_	_	_	6	13	4	22	18	က္	33	0	က	39	2	· ග	24	0		
Leishmania-	В	0	0 2	_	0 5	4 296	0	_	14 439	3 104	0	0	0	0	0	0	0	0	18 553	0 3	22 770	4 443	1 3	9 222	1 149	0 2	0	78 3227	
	A	38	0	26	13	19	17	81	27 1	69	30	9	2	23	2	45	36	22		2	55 2	30	35	94	တ	65	16		
Meningitis	В	က	120	2	_	~		00	7		က						က	2	241	29	2	က	က	6	119		_	1334	
Me	⋖	က	~	2	0	0	0	2	0	0	_	0	0	0	0	0	_	~	က	က	က	~	_	~	က	2	0	28	
Chickenpox	В	485	392	547	356	135	222	269	277	322	203	12	10	41	00	124	112	80	209	120	259	133	328	148	328	764	207	6819	
Chic	∢	18	22	18	9	_	4	1	4	2	0	0	0	_	_	3	က	2	16	2	9	2	0	2	∞	20	4	168	
H. Rabiies	В	0	0	~	2	0	0	~	2	0	_	2	0	0	2	2	~	0	4	~	_	~	0	~	2	~	0	25	
	⋖	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	~	0	0	0	0	0	~	
Viral Hep.	В	0	10	7	<del>-</del>	00	6	10	7	20	7	0	_	4	0	21	2	03	7	4	4	52	44	45	28	12	4	346	
	4	0	_	~	0	0	0	0 0	7	2	0	0	0	0 9	0	0	0	0	0	0 9	0	0	0	- 2	7	0 0	0	10	
Typhus F.	В	0 8	0 11	0 8	2 31	0 5	0 39	3 110	0 46	1 25	3 472	0 11	0 13	0 5	0 11	0 2	0 2	0 12	2 30	1 35	0 30	0 2	1 40	0 31	0 27	0 30	0 5	3 1041	
	A					88					18	0	25 (	93 (	0 89	) 69												_	
Leptospirosis	В	12 443	34 688	24 727	2 220	0 8	2 152	21 771	5 422	9 468	0 1	_	2 2	1 9	9 0	2 6	2 173	0 136	27 590	6 222	3 388	0 237	3 444	0 594	1 1672	14 661	1 67	2 9455	
	A				6	2	2		ω	8	2	2	9	2	σ	4	က	_		က	က	9	9	9	0 51		00	9 232	
F. Poisoning	В	0 22	0 77	0 37	0 59	27	205	0 98	2 48	0 28	0 35	0	0	0 22	0 18	1 64	0 23	2 11	0 351	0	0 43	26	0 56	86	30	14	0 28	1419	
E.	4					~	_									4						~		_	_	_		4	
En. Fever	В	48	14	36	6	8	10	12	2	2	27	2		2	0	7	0	3	3	3	2	_	00	3	80	10	2	1 226	
	⋖	0	0	2	0	0	0	0	0	0	~	0	0	0	0	0	0	0	0	0	0	0	_	0	0	0	0	4	
Encephalitis	В		33	2	2	_	7	22	4	9	2	0	0	_	0	15	က	_	35	4	9	က	00	4	00	6	0	190	
Enc	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	_	0	0	_	0	0	0	2	0	_	_	0	9	
Dysentery	В	35	38	29	34	14	. 127	45	28	10	29	17	4	13	6	115	32	16	47		33	22	35	18	102	23	17	943	
2	4	0	7	0 9	0	0	4	0	0	0	7	0	_	0	0	0	2	0	0	1	7	~	~	0	3	1	0	17	
Dengue Fever	В	9732	4586	2405	3879	669	315	1839	750	1001	5282	291	287	170	205	1460	240	640	2012	1016	699	351	758	815	2455	1789	089	44326	
Deng	∢	180	95	36	68	7	5	27	14	36		_	5	က	0	13	2	က	16	28	5	_	9	40	42	20	~	899	
RDHS		Colombo	Gampaha	Kalutara	Kandy	Matale	Nuwara Eliya	Galle	Hambantota	Matara	Jaffna	Kilinochchi	Mannar	Vavuniya	Mullaitivu	Batticaloa	Ampara	Trincomalee	Kurunegala	Puttalam	Anuradhapura	Polonnaruwa	Badulla	Monaragala	Ratnapura	Kegalle	Kalmunai	SRILANKA	

Source: Weekly Returns of Communicable Diseases (esurvillance.epid.gov.Ik). T=Timeliness refers to returns received on or before 18th Oct, 2024 Total number of reporting units 358 Number of reporting units data provided for the current week. B = Cumulative cases for the year.

Table 2: Vaccine-Preventable Diseases & AFP

12th - 18th Oct 2024 (42nd Week)

Disease	No. of Cases by Province										Number of cases during same	Total number of cases to date in	Total num- ber of cases to date in	Difference between the number of cases to date	
	W	С	S	N	Е	NW	NC	U	Sab	week in 2024	week in 2023	2024	2023	in 2024 & 2023	
AFP*	00	01	00	00	01	01	00	00	00	03	00	63	72	-12.5%	
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Mumps	00	03	00	00	01	01	01	00	00	06	06	236	180	31.1 %	
Measles	00	01	00	00	00	00	00	00	00	01	24	286	638	-55.2 %	
Rubella	00	00	00	00	00	00	00	00	00	00	00	02	05	-60%	
CRS**	00	00	00	00	00	00	00	00	00	00	00	00	02	0 %	
Tetanus	00	00	00	00	00	00	00	00	00	00	00	05	06	-16.6 %	
Neonatal Tetanus	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Japanese Enceph- alitis	00	00	00	00	00	00	00	00	00	00	00	09	02	350 %	
Whooping Cough	00	00	00	00	00	00	00	00	00	00	00	56	07	700 %	

#### Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, MT: Matara, JF: Jaffna,

KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalmunai, KR: Kurunegala, PU: Puttalam,

AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS,

Special Surveillance: AFP\* (Acute Flaccid Paralysis ), Japanese Encephalitis

CRS\*\* =Congenital Rubella Syndrome

NA = Not Available

### Number of Malaria Cases Up to End of October 2024,

02

## All are Imported!!!

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication

#### ON STATE SERVICE

Dr. H. A. Tissera Actg. CHIEF EPIDEMIOLOGIST EPIDEMIOLOGY UNIT 231, DE SARAM PLACE COLOMBO 10